BCR and diffuse large B-cell lymphoma: Mechanisms underlying BCR hyperactivity have been established in diffuse large B-cell lymphoma (DLBCL) such as activating mutations in components of the BCR pathway7–9, and in B-cell chronic lymphocytic leukemia (B-CLL) with self-recognition of the BCR10.